MediGene Signs Agreement with Meditrina for the Commercialization of Veregen® in Greece and Cyprus
(Thomson Reuters ONE) -
MediGene AG / MediGene Signs Agreement with Meditrina for the Commercialization of Veregen® in Greece and Cyprus processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, April 01, 2010.The biotech company MediGene AG (Frankfurt,
Prime Standard, TecDAX) has signed a license and supply agreement with Meditrina
Pharmaceuticals for the supply and commercialization of Veregen(®) in Greece and
Cyprus. Meditrina will promote and distribute Veregen(®) for the treatment of
genital warts in both territories. Upon the achievement of specific milestones,
MediGene will be entitled to successive payments totaling up to 900 thousand
euros, and will receive the first milestone payment upon the initiation of the
approval procedure in Greece. In addition, MediGene will supply Meditrina with
finished product and will receive double-digit royalties on net sales. MediGene
believes that Greece is the sixth largest potential European market for
Veregen(® )sales volume.
MediGene has already entered into marketing partnerships for Veregen(®) with
Nycomed, Inc. for the USA, Solvay (acquired by Abbott on February 15, 2010) for
Germany, Austria and Switzerland, Juste S.A.Q.F for Spain and Portugal and Teva
Pharmaceuticals Industries Ltd. for Israel.
Veregen(® )is already available and on the market in the USA and in Germany, and
market launch in Austria is planned for the summer of 2010. A second wave of
marketing applications within the European mutual recognition procedure is
expected in the second half of 2010, with Germany serving as the Reference State
in this process.
Veregen(®):
Veregen(®) (previously Polyphenon E(®) Ointment) for the topical treatment of
external genital warts is a concentrate of catechins with a complex defined
composition extracted from green tea leaves. MediGene acquired the basic rights
to the active ingredient in Veregen(®) from the Canadian company Epitome
Pharmaceuticals, Inc. in 1999, and was solely responsible for the drug's
preclinical and clinical development, as well as for the approval process.
Moreover the patent protection was further upgraded by a number of proprietary
inventions.
Meditrina:
Meditrina is a privately held, growing pharma company, which was founded in
2005 and is focusing on in-licensing, marketing and sales of pharmaceutical
products. Among others, the company is specialized in the fields of gynecology,
dermatology and oncology. For further information about Meditrina please see
www.meditrina.gr.
This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene and Veregen(®) are registered trademarks of MediGene AG, Polyphenon
E(®) is a registered trademark of Mitsui Norin Co. Ltd. These trademarks may be
owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDax)
biotechnology company located in Martinsried/Munich, Germany, with subsidiaries
in Oxford, UK and San Diego, USA. MediGene is the first German biotech company
to have drugs on the market which are distributed by partner companies. It has
several drug candidates in clinical development and possesses innovative
platform technologies. MediGene focuses on clinical research and development of
novel drugs with focus on oncology.
Contact MediGene AG
Email: investor(at)medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
[HUG#1400156]
--- End of Message ---
MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090;ISIN: DE0005020903 ;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="OSISKO ANNOUNCES FRIENDLY TAKE OVER BID TO ACQUIRE BRETT RESOURCESDatum: 01.04.2010 - 02:30 Uhr
Sprache: Deutsch
News-ID 1012379
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 110 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MediGene Signs Agreement with Meditrina for the Commercialization of Veregen® in Greece and Cyprus
"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
